Targeted Chemotherapy Delivery Platform. Igor Sherman, PhD President & CEO Richard Potts, Chairman
|
|
- Brianne Wilcox
- 8 years ago
- Views:
Transcription
1 Targeted Chemotherapy Delivery Platform Igor Sherman, PhD President & CEO Richard Potts, Chairman 2014
2 Change in Age Adjusted US Death Rates by Cause Almost unchanged over 50 years Source: U.S. National Center for Health Statistics, National Vital Statistics Reports, Vol. 59, No. 4, March 16, 2011.
3 THE STORY Harnessing Nature AFP is a human protein produced by the embryo during fetal development and serves at least two critical functions: 1. Picks up nutrients from the mother and delivers them to the embryo; and 2. Is thought to normalizes the immune system responses so the mother s immune cells don t attack the embryo. AFP circulates in the maternal bloodstream and picks up free fatty acids, steroids, and other hydrophobic substances, needed by rapidly dividing cells. The loaded AFP continues to circulate until it finds receptors which are exclusively found on all embryonic cells. It then transports the nutrients into the cell and releases them once inside. When the embryo matures the production of AFP stops and the receptors disappear. Cancer cells in many ways can be viewed as reverting to an embryonic state and > 80% of solid and liquid tumors (leukemia, lymphoma) express AFP receptors on their surface while healthy cells do not. By attaching a chemotherapy payload to AFP we can selectively deliver toxins to cancer cells. This targeted delivery prevents chemotherapy from entering healthy cells resulting in increased efficacy and a significant reduction in toxicity. It is well known that symptoms of autoimmune diseases (Multiple Sclerosis, Myasthenia Gravis, Lupus, Arthritis etc.) go into remission during pregnancy and return soon after. This seems to correlates very well with the rise and fall of AFP. In various pre-clinical models of autoimmune diseases administration of AFP is a very effective therapy. ACT has exclusive worldwide rights to recombinant human alpha fetoprotein (rhuafp).
4 ACT IS A DRUG DELIVERY COMPANY WITH A TARGETED CHEMOTHERAPY DELIVERY PLATFORM Toronto-based company (MaRS Discovery District) Company Background Exclusive worldwide rights to targeted delivery platform Alpha Fetoprotein (AFP) AFP - shuttle protein that selectively targets cancer cells (most solid and liquid tumors) Paclitaxel - generic chemotherapy payload Lead Asset ACT-901 (AFP + Paclitaxel) In-licensed technology with over $100 million spent on development, demonstrated safety in over 400 patients, 20+ international patents, large Drug Master file already with FDA including manufacturing, toxicology, and human safety mitigated development path Leading world authority in oncology lends his support and agrees to be the principal investigator for clinical studies Financing To Date $3.05M equity previously completed 52.5 million Shares Outstanding $1.0M in Federal Government funding (FedDev, IRAP) SRED Leverage refundable tax credits 35% of expenditures
5 Management Team OUTSOURCED / RESOURCES MANAGEMENT Richard Potts Chairman Igor Sherman President & CEO Virtual company ensuring efficient cash utilization and a focus on asset development via external (i.e. outsourced) support
6 Management Richard Potts Chairman Demonstrated a rich blend of leadership roles with a track record of management, finance and marketing of growth companies across a diverse spectrum of industries, including biotechnology, medical and information technology. Mr. Potts has co-founded, established strategic plans, secured multi-million dollars in financing, public listings and facilitated partnerships as a founder, owner and executive in numerous companies in the knowledge-based industry. Dr. Igor Sherman, President & CEO Extensive experience and expertise in the pharmaceutical and biotechnology industries, particularly in oncology. Prior to ACT, Dr. Sherman was Director of Clinical Research and Director of Scientific Affairs for YM Biosciences Inc., where he was responsible for preclinical and clinical development, as well as registration strategies for all oncology and pain products in YM Biosciences portfolio. Dr. Sherman was also Scientific Director of Oncology for AstraZeneca Canada Inc.
7 Life Science Risk Mitigation Seeking Alpha TO SUCCEED IN LIFE SCIENCE MITIGATE RISK Scientific Risk combination of safe targeted delivery platform (AFP) and effective chemotherapy Manufacturing Risk AFP manufacturing is outsourced and was already cleared by the FDA Regulatory Risk large existing drug master file with the FDA Clinical Risk demonstrated safety in ~400 patients and carries an approved generic chemotherapy drug as its payload Intellectual Property Risk 20+ patents in place plus 12 years exclusivity Financing Risk Very low ~$25 million to complete Phase II and apply for accelerated approval as an orphan drug Execution Risk outsourced development pathway manufacturing, Clinical Research Organizations (CROs), teaching hospitals.
8 ACT-901 Animation
9 Pipeline Overview Therapy Indication Partners Discovery Pre-clinical Phase I Phase II ACT-901 (AFP + Paclitaxel) Targeted Oncology Solid and liquid tumors Collaboration University Health Network ACT-902 (AFP+Thapsigargin) Targeted Oncology Solid and liquid tumors Collaboration University Health Network ACT-903 (AFP+Linker+Myatansinoid) Targeted Oncology Solid and liquid tumors Collaboration Polytherics U.K. AFP Autoimmune Rheumatoid Arthritis Looking to Partner out Myasthenia Gravis (muscle weakness) Multiple Sclerosis, Uveitis, other
10 Lead Asset ACT-901 Lead Asset - ACT-901 (AFP + Paclitaxel) AFP a shuttle protein that targets AFP receptors on cancer cells Majority of solid and liquid cancer cells (>80%) have AFP receptors AFP receptors are only present on cancer cells - healthy cells do not have AFP receptors Paclitaxel is a widely used generic chemotherapy ACT-901 combines its highly targeted transporter protein AFP with a paclitaxel payload This payload is delivered selectively to cancer cells Benefits of this Targeted Approach: Reformulation of two well-known compounds Fast Track Approval Currently in development for ovarian cancer Orphan Drug / Breakthrough Therapy Will expand to Non-Small Cell Lung Cancer, Prostate, Colon and other indications Overcomes chemotherapy drug resistance as delivery bypasses membrane pumps AFP is non-immunogenic in humans - demonstrated in over 400 patients (as safe as placebo) Frequency of treatment driven by efficacy, not toxicity avoidance Treatment expected to minimize pain, suffering and healthcare cost
11 ACT-901 is the 3 rd Generation Paclitaxel Therapy Generation Image Formulation Maximum Tolerated Dose Peak Sales 1 st Taxol Paclitaxel Cremophor EL excipient: Polyoxyethylated castor oil 175 mg/m2 ~ $1.6B (WW in 2000) 2 nd Abraxane (Albumin+paclitaxel) Biological polymer: Donor-derived human serum albumin (HSA) 260 mg/m2 Est. >$1.7B* (US) ($430M in 2012) Mean size 130nm 3 rd ACT-901 (AFP+paclitaxel) Biological Targeted carrier No MTD Targeted Therapy Conversion of Abraxane sales + new indications Mean size ~8 nm
12 Evidence of Safety of AFP (delivery platform) in Humans 300 Patient Clinical Study of Delivery Platform (AFP) A randomized, double-blind, placebo-controlled trial of a recombinant version of human alpha-fetoprotein in patients with active rheumatoid arthritis as conducted. Patients were injected with either MM-093 (AFP) or a placebo subcutaneously every weeks for 12 weeks. Results AFP was well tolerated The incidence of adverse events was similar in the AFP and placebo groups Most common adverse events were headaches, upper respiratory tract infections, musculoskeletal pain and injection site reactions L C Pollard, J Murray, M Moody, E J Stewart, E H S Choy Ann Rheum Dis 2007;66:
13 Evidence of Efficacy Free dox IC50=25.0 ug/ml AFP-dox IC50=2.7 ug/ml Overcoming multidrug resistance in human ovarian cell line Chemo-resistant ovarian carcinoma cell line SKVLB IC50 (dose that kills 50%): AFP-Dox = 2.7 ug/ml IC50 for Dox = 25.0 ug/ml (of Dox equivalent) Moskaleva et al. (1997), Cell Biol. Internat., 21,
14 UHN Princess Margaret Cancer Centre Evidence of Efficacy in vivo Tumor Volume Daily treatment mg/kg of Paclitaxel for 2 weeks from days 7 to 21 Treatment Period
15 % Survival Evidence of Efficacy in vivo Survival Results UHN Princess Margaret Cancer Centre Saline Paclitaxel 180 mg/week Paclitaxel 300 mg/week ACT-901(AFP+Paclitaxel) 180 mg/week (of Paclitaxel) Treatment Period Days
16 Why Invest in Alpha Cancer Technologies? 1 The Return TOP 8 CANCER DEALS (AT PRECLINICAL STAGE) IN LAST 4 YEARS - VALUATION RANGE ~$500M - $1.2B ABRAXANE (ALBUMIN + PACLITAXEL) VALUATION ~$6B VALUED ASSET FOR CELGENE 2 Time to Market ACCELERATED APPROVAL - ORPHAN DRUG FOR OVARIAN CANCER IN THE US AND EUROPE BY ~2018 MUCH SHORTER PATH WITH GREATER CERTAINTY DUE TO: DRUG DELIVERY TECHNOLOGY, FOCUS ON ORPHAN INDICATION, AND EXISTING DRUG MASTER FILES WITH FDA FOR AFP + PACLITAXEL 3 Cost VIRTUAL COMPANY MODEL WITH EFFICIENT CLEARLY DEFINED CLINICAL DEVELOPMENT PATHWAY 4 Risk SIGNIFICANTLY MITIGATED RISK IN EVERY AREA OF DEVELOPMENT ~ INCLUDING EXISTING 400 PATIENT SAFETY DATA DELIVERY TECHNOLOGY NOT NEW DRUG DEVELOPMENT
17 1 Top Down Valuation Companies Payout* Deal Terms $1B + royalties July Worldwide rights to develop and commercialize Bi-specific T cell engager antibodies against 2 solid tumour targets. $964M + royalties Dec Exclusive rights to develop and commercialize targeted covalent drugs for cancer treatment based on Avila s Avilomics Technology. $912M + royalties Aug Worldwide rights to develop and commercialize cancer drug candidates using Seattle Genetics antibody-drug conjugate program. $815M + royalties Jan Collaboration to discover and develop small molecule drugs against oncology-relevant protein-protein interactions. * Prospective deals include up-front, milestone and royalty payments (on net sales).
18 1 Top Down Valuation cont d Companies Payout* Deal Terms $700M + royalties Jan Collaboration to discover and develop drugs that target tumor metabolism mechanisms. $540M + royalties June Rights to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway. $508M + royalties Aug Exclusive worldwide rights to develop and commercialize drug candidates arising from its PD-1 program for treatment of cancer. $466M + royalties Oct 2010, Dec Exclusive worldwide rights to discover, develop, manufacture and market TAP compounds for the treatment of cancer. * Prospective deals include up-front, milestone and royalty payments (on net sales).
19 1 Comparable - Abraxane ACT-901 Abraxane Valuation Delivery AFP + Paclitaxel Targeted to Receptor on cancer cells only Albumin + Paclitaxel $6 Billion In vivo Study Survival 125% * 84% ** Non-targeted penetrates healthy and cancer cells Delivery amount Low Dose Maximum Tolerated Dose Toxicity Little to none Maximum (Dose dependant) * Princess Margaret Cancer Centre 2012 median survival 45 days compared to 20 days for control at low dose * * AACR Hospital for Sick Children 2013 median survival 59 days compared to 32 days for control at high dose
20 2 Time to Market Preclinical Development Phase I Phase II Expedited Approval Phase III Post-Marketing $$ 2014 Q Q Q Q Prospective partnership(s) to initiate development in other indications or new product(s) Market launch in Canada and select Asia for ovarian cancer Market launch in the US and Europe for ovarian cancer (orphan drug approval) Market launch in US, Canada, Europe and select Asia for NSCLC/prostate/Colon etc. cancer Expedited commercial approval of ACT-901 in US and Europe by targeting orphan disease population Clear clinical development plan will bring ACT-901 to all target markets Co-development/co-marketing with biopharma will facilitate early or later expansion into additional indications
21 3 Cost Proceeds added to Working Capital used as follows: Start Preclinical File to IND $2.0mm ongoing Phase I Study (~14 months) (~35 patients treated to efficacy) $5mm ~Q Phase II Study (Commercialization Ovarian cancer two arms ~220 patients) (~24 months) $18mm ~Q Accelerated Approval ~Q Virtual company ensuring efficient cash utilization and a focus on asset development via external (i.e. outsourced) support
22 4 Risk Mitigation DEVELOPMENTAL RISKS - MITIGATED Efficacy Efficacy of paclitaxel established, as is its widespread use in multiple forms of cancer Enhanced efficacy of ACT-901 vs. free paclitaxel in multiple tumor cell lines and mice with cancer already demonstrated Safety AFP shown to be safe in 400 humans in Phase I/II clinical testing Paclitaxel safety profile (an approved chemotherapy drug) well understood Development Path is Clear Validated targeted chemotherapy platform, delivering an approved chemotherapy drug to cancer cells
23 4 Risk Mitigation cont d MANUFACTURING RISKS - MITIGATED Production of ACT-901 FDA-approved processes for both AFP and paclitaxel Outsourced commercial manufacturing to combine AFP and paclitaxel COMMERCIAL RISKS - MITIGATED Competition ACT-901 will substitute for paclitaxel s established use delivering a targeted and less toxic therapy Pricing & Reimbursement Less expensive compared to other targeted therapy options High probability of reimbursement in target markets
24 News Collaboration for 2 nd Product PolyTherics and Alpha Cancer Technologies Collaborate to Produce Novel Drug Conjugates to Target Tumours ThioBridge linker to attach cytotoxic payloads to alpha fetoprotein London, UK and Toronto, Canada 28 May 2014 PolyTherics Limited ( PolyTherics ), an Abzena company that provides technologies and services to enable the development of better biopharmaceuticals, today announced a collaboration with Alpha Cancer Technologies Inc. ( ACT ), a Canadian company with a targeted drug delivery platform based on alpha fetoprotein ( AFP ). PolyTherics will produce a range of AFP drug conjugates for ACT to test using its proprietary ThioBridge technology.
25 Business Development Checklist Novel targeted chemotherapy delivery platform - AFP Delivery protein fully characterized Mechanism of action well understood Massive safety data in over 400 humans non-immunogenic 20+ international patents in place Receptors found on >80% of all cancers (solid and liquid) Confirmation of efficacy even in drug resistant tumors Demonstrated superior activity at low treatment dose Outsourced FDA approved manufacturing in place Outsourced development underway (reduced burn rate) Significant risk mitigation and short path to value Business Development Checklist Lead asset ACT-901 (AFP+ Paclitaxel) clear path to success ACT
26 For further information, please contact: Richard Potts Chairman Tel: Igor Sherman President and CEO Tel:
27 Forward Looking Statements Caution Regarding Forward Looking Information: Certain statements contained in this material constitute forward looking information within the meaning of applicable Canadian provincial securities legislation (collectively, the "forward looking statements"). These forward looking statements relate to, among other things, ACT's objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward looking statements. These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties and risks related to, the availability of capital, changes in capital markets, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, unproven markets for technologies in development, the cost and supply of raw materials, management of growth, effects of payers ' willingness to pay for products, risks related to regulatory matters and risks related to intellectual property matters. When relying on ACT's forward looking statements to make decisions with respect to ACT, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Such forward looking statements are based on a number of estimates and assumptions which may prove to be incorrect, including, but not limited to, assumptions regarding the availability of financing for research and development companies in addition to general business and economic conditions. These risks and uncertainties should be considered carefully and investors and others should not place undue reliance on the forward looking statements. Although the forward looking statements contained in this material are based upon what management believes to be reasonable assumptions, ACT cannot provide assurance that actual results will be consistent with these forward looking statements. ACT undertakes no obligation to update or revise any forward looking statement.
A Letter from MabVax Therapeutics President and Chief Executive Officer
A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the
More informationNew Advances in Cancer Treatments. March 2015
New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within
More informationCAN-FITE BIOPHARMA LTD.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
More informationIMMUNOMEDICS, 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282
IMMUNOMEDICS, INC. 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 IMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2014 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS Morris
More informationMOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015
Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future
More informationBNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED
ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination
More informationImmunovaccine Inc. (TSX-V: IMV) July 2011
Immunovaccine Inc. (TSX-V: IMV) July 2011 2 Forward Looking Statements This document contains forward-looking information pursuant to applicable securities law. All information that addresses activities
More informationIMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationThe Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
More informationTERM SHEET EXAMPLE. 1 P age
1 P age TERM SHEET EXAMPLE BIOTECHCO Overview & Business Strategy BIOTECHCO (the licensor), located in North Dakota, has a proprietary technology called ZIP that can generate fully human antibodies with
More informationAchieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013
Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory
More informationGenomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
More informationAdaptimmune Reports Full Fiscal Year 2015 Financial Results. - Conference call to be held today at 8:00 AM ET (1:00 PM BST) -
Adaptimmune Reports Full Fiscal Year 2015 Financial Results - Conference call to be held today at 8:00 AM ET (1:00 PM BST) - PHILADELPHIA, Pa. and OXFORD, United Kingdom., October 13, 2015 Adaptimmune
More informationCellectar Biosciences
Cellectar Biosciences NASDAQ: CLRB September 2015 1 Safe Harbor Statement This slide presentation contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation
More information9. WestLB Deutschland Conference. Frankfurt November 16, 2011
9. WestLB Deutschland Conference Frankfurt November 16, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking
More informationTwo-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis
Your contact News Release Barbara Fry Phone +1 905 919 0163 April 29/30, 2009 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple
More informationPain Therapeutics, Inc.
Pain Therapeutics, Inc. Pioneers in Preventing Prescription Drug Abuse Remi Barbier President & CEO June 2014 1 Forward-Looking Statements This presentation contains forward-looking statements within the
More informationAffitech A/S reports financial result for the first six months of 2012
Release no. 23/2012 Affitech A/S reports financial result for the first six months of 2012 Clinical trials sites initiated in Russia in late June 2012 by Affitech s collaboration partner IBC Generium for
More informationThird Quarter, 2015 Update
Third Quarter, 2015 Update November 6, 2015 Forward Looking Statement This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation
More informationargen-x Business Update and First Half 2014 Results
argen-x Business Update and First Half 2014 Results 27 August 2014 Breda, the Netherlands / Ghent, Belgium argen-x N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on
More information18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer
News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck
More informationExelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/
More informationKempen & Co 4 th Healthcare/Life Sciences Conference. Brussels March 29, 2011
Kempen & Co 4 th Healthcare/Life Sciences Conference Brussels March 29, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included
More informationPROMETIC LIFE SCIENCES INC.
PROMETIC LIFE SCIENCES INC. Investor Update July to September 2002 This present release must be considered as the quarterly report to shareholders. 1. Letter to Shareholders Dated November 21, 2002 2.
More informationMOLOGEN AG German Equity Forum 2015
German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015 We are Pioneers in the Field of Immunotherapies Biotechnology company with focus on immunotherapies
More informationNot All Clinical Trials Are Created Equal Understanding the Different Phases
Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact
More informationTheravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results and Provides Business Update
August 10, 2015 Theravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results and Provides Business Update DUBLIN, IRELAND -- (Marketwired) -- 08/10/15 -- Theravance Biopharma, Inc. (NASDAQ:
More informationBioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma
BioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma 2 Novozymes solutions dedicated to the biopharmaceutical industry
More informationCellectar Biosciences
Cellectar Biosciences NASDAQ: CLRB October 2015 1 Safe Harbor Statement This slide presentation contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation
More informationNews Release. Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma
Your Contacts News Release Merck KGaA, Darmstadt, Germany Media: Markus Talanow +49 6151 72 7144 Investor Relations +49 6151 72 3321 Pfizer Inc., New York, USA Media: Sally Beatty +1 212 733 6566 Investor
More informationDaiichi Sankyo to Acquire Ambit Biosciences
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please
More informationOPKO Health to Acquire Bio-Reference Laboratories
OPKO Health to Acquire Bio-Reference Laboratories - Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy - Acquisition
More informationDecision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
More informationDeutsches Eigenkapitalforum. Frankfurt November 22, 2011
Deutsches Eigenkapitalforum Frankfurt November 22, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking
More informationNovel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation
Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation Hans S. Keirstead President, NeoStem Oncology NeoStem Presented by GTC, a conference production company 626-256-6405
More informationexactly. The need for efficiency in developing effective new therapeutics has never been greater.
exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,
More informationManagement Discussion and Analysis of the Financial Condition and Results of Operations
Management Discussion and Analysis of the Financial Condition and Results of Operations Fiscal 2014 First Quarter for the three months ended July 31, 2013 Table of Contents Overview 1 Forward looking Statements
More informationBNC105 PHASE II RENAL CANCER TRIAL RESULTS
ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient
More informationWhat You Need to Know About Lung Cancer Immunotherapy
What You Need to Know About Lung Cancer Immunotherapy Lung.org/immunotherapy What is immunotherapy? Immunotherapy for cancer, sometimes called immune-oncology, is a type of medicine that treats cancer
More informationMedical Therapies Limited EGM Presentation
Medical Therapies Limited EGM Presentation Maria Halasz Chief Executive Officer 5 May 2009 1 Agenda 1. Company information 2. Recent developments 3. Business strategy 4. Key value inflection points for
More informationNEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
More informationPharmaceutical Report Royalty Purchasing Industry. Thomas R. Wells
Pharmaceutical Report Royalty Purchasing Industry Thomas R. Wells Table of Contents Industry Overview 2 How Transactions Work 2 Advantages & Disadvantages for Inventors and Investors 4 Major Investors
More informationCLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this
More informationCompany Update. March 2011
Company Update March 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various
More informationPennino Corporation TECHNOLOGY TO IMPROVE LIFE
Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety
More informationBayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups
Open Innovation@BayerHealthCare Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to
More informationFederal Funding for Technological Revolutions: Biotechnology and Healthcare Highlights
ADVANCED TE CHNOLOGY P ROGRAM The Advanced Technology Program Federal Funding for Technological Revolutions: Biotechnology and Healthcare Highlights April 2006 National Institute of Standards and Technology
More informationDNB Markets 5 th Annual Health Care Conference, 11 December 2014 CEO Luigi Costa
DNB Markets 5 th Annual Health Care Conference, December 0 CEO Luigi Costa Nordic Nanovector ASA Kjelsåsveien 68 B, 088 Oslo, Norway - www.nordicnanovector.com Forward-looking statements This presentation
More informationSORRENTO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationCompany Presentation June 2011 Biotest AG 0
Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and
More informationCommercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019
Brochure More information from http://www.researchandmarkets.com/reports/1314569/ Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive
More informationFORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2011
More informationNational MS Society Information Sourcebook www.nationalmssociety.org/sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers
More informationOvarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from
More informationPaul K. Wotton, Ph.D President and Chief Executive Officer May 2012 AMEX: AIS
Paul K. Wotton, Ph.D President and Chief Executive Officer May 2012 AMEX: AIS Safe Harbor Statement This presentation may contain forward-looking statements which are made pursuant to the safe harbor provisions
More informationWhy Are Drugs So Expensive? Learning About the Drug Development Process
Why Are Drugs So Expensive? Page 1 of 92 Why Are Drugs So Expensive? Learning About the Drug Development Process written by: Ann Newman Seventh Street Development Group This product is for your Personal
More informationBiotest Group. H1 2014 Conference call 12 August 2014
Biotest Group H1 2014 Conference call 12 August 2014 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset
More informationGuidance for Industry
Guidance for Industry S9 Nonclinical Evaluation for Anticancer Pharmaceuticals U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
More informationAeterna Zentaris. 11 th Annual Needham Healthcare Conference April 3, 2012. Committed to cure
11 th Annual Needham Healthcare Conference April 3, 2012 Forward-Looking Statements This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities
More informationTransgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO
Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 23 July 1998 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL
More informationIf you were diagnosed with cancer today, what would your chances of survival be?
Q.1 If you were diagnosed with cancer today, what would your chances of survival be? Ongoing medical research from the last two decades has seen the cancer survival rate increase by more than 40%. However
More informationAdocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro
PRESS RELEASE Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro BioChaperone Lispro is significantly faster than Humalog in type I diabetic patients;
More informationSPHERIX INCORPORATED (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationNONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
More informationRoche Position on Human Stem Cells
Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with
More informationGuidance for Industry
Guidance for Industry IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer U.S. Department of Health and Human Services Food and Drug Administration Center
More informationGene Silencing Oligos (GSOs) Third Generation Antisense
Gene Silencing Oligos (GSOs) Third Generation Antisense Walter R. Strapps, Ph.D. Executive Director, RNA Therapeutics Idera Pharmaceuticals Cambridge, MA NASDAQ: IDRA www.iderapharma.com Idera is a leader
More informationTransgene in 2007: Partnership and Refinancing Position the Company for its Future Development
Strasbourg, 11 March 2008 Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development Strasbourg, France, March 11, 2008 Transgene (Euronext Paris: FR0005175080) announces
More informationa Phase 2 prostate cancer clinical trial is ongoing. Table 2: Squalamine vs Standard-of-care literature
PRODUCT FACT SHEET Spring 2007 MISSION STATEMENT Genaera Corporation is a biopharmaceutical company with a focus on metabolic and respiratory diseases. The compounds in the Genaera pipeline address signal
More informationOverview of Phase 1 Oncology Trials of Biologic Therapeutics
Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of
More informationBiosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies
Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Fern Barkalow, Ph.D, Senior Analyst, Oncology Citeline One of the biggest challenges facing biosimilar drug developers is
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies
More informationPfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology. November 17, 2014
Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology November 17, 2014 Forward-looking statements Our discussions during this conference call will
More informationDec. 9, 2013, 11:00 a.m. EST
Dec. 9, 2013, 11:00 a.m. EST Portola Pharmaceuticals Announces New Phase 2 Results Confirming Immediate, Dose-Dependent and Well-Tolerated Reversal of Anticoagulation Activity of XARELTO(R) (rivaroxaban)
More informationThe Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry
Talentmark Consulting Product Driven People Solutions Press Release The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Cambridge
More informationCheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early
April 21, 2015 CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early Opdivo Demonstrates Superior Overall Survival Compared to Docetaxel in Patients with Previously-Treated
More informationTaking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset
Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Introduction In this era of strategic development deals, inventiv Health has significantly broadened
More informationTABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and
More informationCommerzbank Sector Conference. Frankfurt August 30, 2011
Commerzbank Sector Conference Frankfurt August 30, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking
More informationCorporate Presentation June 2, 2015
Corporate Presentation June 2, 2015 SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these
More informationUBS Global Life Sciences Conference 2011. New York September 19, 2011
UBS Global Life Sciences Conference 2011 New York September 19, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the
More informationFDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable
More informationNew York Bio Conference 2016. Mark J. Alles Chief Executive Officer
New York Bio Conference 2016 Mark J. Alles Chief Executive Officer Great Progress AGE 72 World Life Expectancy 2005-2014* 17 new drugs for rare diseases 71.5 71 Two new MS drugs First drug to target root
More informationRegulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Office of Vaccines Research and Review Center for Biologics Evaluation and Research U.S. Food
More informationINTERIM REPORT, 1 January - 30 June 2003
PRESS RELEASE, 9 July INTERIM REPORT, 1 January - 30 June In May, Medivir reached a licensing agreement on MIV-210 with GlaxoSmithKline; EUR 6 m was received upon signing and up to EUR 86 m on the achievement
More informationAFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement
FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:
More informationCCS net sales increased to SEK 42.1 (35.0) m. Profit after financial items was SEK 8.8 (3.1) m.
PRESS RELEASE, 29 April INTERIM REPORT, 1 January - 31 March MIV-210 producing positive results in ongoing phase I trial. More opportunities for Cathepsin S inhibitor. Successes in the explorative activities
More informationLOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT
LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of
More informationQ4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO
Q4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO 1 PCI BIOTECH Important notice and disclaimer This presentation may contain certain forward-looking statements and forecasts based
More informationAn Introduction to Valuations
An Introduction to Valuations PREPARED FOR ROCKY MOUNTAIN BIOBOOSTER MAY 9 TH, 2012 An ICON plc Company Agenda Introductions Valuation methods When is a valuation appropriate? How do you maximize your
More informationDeveloping Innovative Therapeutics for People with Orphan Liver Disease
Developing Innovative Therapeutics for People with Orphan Liver Disease PIPELINE PROGRESS AND FIRST QUARTER 2015 EARNINGS UPDATE NASDAQ: OCRX Forward-Looking Statements Certain statements in this presentation
More informationGroundbreaking Collaborative Clinical Trial Launched
Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)
More informationLocalised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment
Localised Cancer Treatment PCI Biotech Amphinex a new product for localised cancer treatment Disclaimer This document (the Presentation ) has been produced by PCI Biotech Holding ASA (the Company ). The
More informationBuilding A Focused Oncology Business
Building A Focused Oncology Business David Meek President, Oncology Our Strategic Priority: To be at the forefront of patient-centric innovation, bringing life-changing cancer therapies to patients with
More informationFACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN
FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN General Pantarhei Bioscience B.V. is an emerging specialty pharmaceutical company with a creative approach towards drug development. The Company
More informationAcucela Inc. IR Meeting
Acucela Inc. IR Meeting Tokyo May 20, 2015 Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening
More informationMorphoSys Proprietary Development Update
September 8, 2015 MorphoSys Proprietary Development Update 1 Safe Harbor This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking
More informationMid-Clinical Stage Antiviral Drug Development Company
BIOTRON LIMITED (ASX:BIT) Mid-Clinical Stage Antiviral Drug Development Company Investor Update 20 August 2015 Dr Michelle Miller Managing Director +61 412 313329 mmiller@biotron.com.au www.biotron.com.au
More informationThe Ultimate Healthcare & Biotechnology Event in 2010. Deborah Rathjen CEO & Managing Director 24 March 2010
The Ultimate Healthcare & Biotechnology Event in 2010 Deborah Rathjen CEO & Managing Director 24 March 2010 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking"
More information